Early Phase Cancer Immunotherapy

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.

Publication Year: 2018
Imprint: Springer International Publishing
Format: H
Weight (Gram): 6387